Browse Category

NASDAQ:ALNY News 20 December 2025 - 13 January 2026

Alnylam stock dips as Amvuttra sales miss some forecasts; 2026 outlook in focus

Alnylam stock dips as Amvuttra sales miss some forecasts; 2026 outlook in focus

Alnylam shares fell 0.1% to $370.39 Tuesday afternoon after the company projected 2026 net product revenue between $4.9 billion and $5.3 billion. Preliminary 2025 sales were disclosed at $2.987 billion. Analysts remained mostly positive but flagged possible weakness for Amvuttra next quarter. The update came as Alnylam outlined its new five-year strategy at the J.P. Morgan Healthcare Conference.
Alnylam stock sinks nearly 7% after Amvuttra revenue miss; what to watch next for ALNY

Alnylam stock sinks nearly 7% after Amvuttra revenue miss; what to watch next for ALNY

Alnylam shares fell 6.7% to $370.91 after preliminary fourth-quarter sales for Amvuttra missed Wall Street estimates. The company reported about $827 million in Amvuttra revenue, below analyst expectations of $852 million. Alnylam set 2026 product revenue guidance at $4.9 billion to $5.3 billion and outlined a new five-year plan. Full results are due in February.
Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short

Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short

Alnylam shares fell 6.7% to $370.91 in after-hours trading Monday after the company issued 2026 sales guidance and launched its “Alnylam 2030” plan. Preliminary Q4 sales of Amvuttra reached about $827 million, missing some estimates. Management projected 2026 net product revenue of $4.9–$5.3 billion, mostly from its TTR franchise. The company targets over 25% annual revenue growth through 2030.
Alnylam Pharmaceuticals (ALNY) Stock After Hours: Nasdaq-100 debut, fresh catalysts, and what to watch before Tuesday’s open (Dec. 23)

Alnylam Pharmaceuticals (ALNY) Stock After Hours: Nasdaq-100 debut, fresh catalysts, and what to watch before Tuesday’s open (Dec. 23)

Alnylam Pharmaceuticals closed up 1.87% at $407.73 Monday, its first session as a Nasdaq-100 constituent. The stock slipped 0.12% after hours. Index inclusion drove trading volume to about 1.05 million shares. Alnylam recently announced a $250 million expansion of its Massachusetts manufacturing site.
Alnylam Pharmaceuticals (ALNY) Stock on Dec. 22, 2025: Nasdaq-100 Debut, AMVUTTRA Momentum, Analyst Price Targets and the 2026 Outlook

Alnylam Pharmaceuticals (ALNY) Stock on Dec. 22, 2025: Nasdaq-100 Debut, AMVUTTRA Momentum, Analyst Price Targets and the 2026 Outlook

Alnylam Pharmaceuticals joined the Nasdaq-100 Index on Dec. 22, 2025, as the annual reconstitution took effect before the market opened. Shares traded near $405.60, up 1.3% from the prior close. The company recently announced a $250 million U.S. manufacturing expansion and reported strong adoption of its AMVUTTRA therapy for transthyretin amyloidosis.
Alnylam Pharmaceuticals (ALNY) Stock: Nasdaq-100 Entry, Amvuttra Momentum, Analyst Targets and Key Risks to Know Before the Dec. 22, 2025 Market Open

Alnylam Pharmaceuticals (ALNY) Stock: Nasdaq-100 Entry, Amvuttra Momentum, Analyst Targets and Key Risks to Know Before the Dec. 22, 2025 Market Open

Alnylam Pharmaceuticals joins the Nasdaq-100 before the U.S. market opens Dec. 22, prompting index-tracking funds to adjust positions. Shares last closed at $400.23. The company’s drug Amvuttra recently secured routine NHS use in England and Health Canada approval for ATTR cardiomyopathy. Alnylam also announced a $250 million manufacturing expansion and new FDA recognition for its technology platform.
Alnylam Pharmaceuticals (ALNY) Stock After Hours: What Happened After the Dec. 19, 2025 Close — and What to Watch Before the Next Market Open

Alnylam Pharmaceuticals (ALNY) Stock After Hours: What Happened After the Dec. 19, 2025 Close — and What to Watch Before the Next Market Open

Alnylam Pharmaceuticals (ALNY) closed Friday, Dec. 19, 2025, at $400.23, up 1.15% on heavy volume of 12.6 million shares, with little movement after hours. The Nasdaq-100 reconstitution takes effect before the U.S. market opens Monday, Dec. 22, adding Alnylam to the index. Friday’s session saw record derivatives expirations, amplifying trading volume.
20 December 2025

Stock Market Today

Ondas Inc stock jumps 14% as ONDS traders weigh defense deal news before Monday

Ondas Inc stock jumps 14% as ONDS traders weigh defense deal news before Monday

8 February 2026
Ondas shares surged 14.3% to $9.69 Friday, with 88 million shares changing hands after defense and drone contract announcements. The stock rebounded from double-digit drops earlier in the week, swinging between $8.45 and $9.76 during the session. After-hours trading was flat. Investors await Monday’s open for signs of continued momentum.
MARA stock braces for Monday after 22% jump as bitcoin rebounds above $70,000

MARA stock braces for Monday after 22% jump as bitcoin rebounds above $70,000

8 February 2026
MARA Holdings shares jumped 22.3% to $8.24 on Friday as bitcoin rebounded above $70,000 after a sharp drop. Blockchain data showed MARA-linked wallets moved about 1,317 bitcoin during the selloff. Peers Riot Platforms and CleanSpark also rallied. U.S. inflation data due Friday could further shift risk sentiment.
Go toTop